Phase II trial designs in the presence of stratification [3]

Statistics in Medicine

Volumn 25, Issue 18, 2006, Pages 3220-3222

  Tan, Say Beng ^a,b   Machin, David ^a,b,c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b Clinical Trials and Epidemiology Research Unit   (Singapore)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE;

BAYES THEOREM; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; METASTASIS; METHODOLOGY; NASOPHARYNX CARCINOMA; OUTCOMES RESEARCH; PROBABILITY; PROGNOSIS; SAMPLE SIZE; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

BAYES THEOREM; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; RESEARCH DESIGN;

EID: 33748620963     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2498     Document Type: Letter

References (3)

1. London WB, Chang MN. One and two-stage designs for stratified phase II clinical trials. Statistics in Medicine 2005; 24:2597-2611.
2. Foo KF, Tan EH, Leong SS, Wee JT, Tan T, Fong KW, Koh L, Tai BC, Lian LG, Machin D. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Annals of Oncology 2002; 13:150-156.
3. Tan SB, Machin D, Tai BC, Foo KF, Tan EH. A Bayesian re-assessment of two phase II trials of gemcitabine in metastatic nasopharyngeal cancer. British Journal of Cancer 2002; 86:843-850.